Effects of intraperitoneal injection of gold nanoparticles in male mice


1 Department of Biology, Payame Noor University, Tehran, Iran

2 Young Researchers & Elite Club, Khorasgan Branch, Islamic Azad University, Isfahan, Iran

3 Department of Medical Technology, Isfahan University of Medical Sciences, Isfahan, Iran

4 Department of Biology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran


There is a rising use of gold nanoparticles (AuNPs) in goods and in the medical fields but there is concern about the toxicity of them. So in this study spherical AuNPs with 3 different concentrations were applied for investigating their effects in vivo.
Materials and Methods: 
40 male albino mice were randomly divided into sham, control, 25 ppm, 50 ppm, 100 ppm groups and were treated by intraperitoneal injection for period of 14 days. Blood was taken for measuring of glutamate oxaloacetate transaminase and glutamate pyruvate transaminase (SGOT and SGPT) enzyme levels and Complete Blood Count (CBC).
After the treatment and comparing groups with sham group, in 50 ppm group significant increases on RBC, HCT, HGB, MCHC and in 25 ppm group significant increase on MCHC and significant decrease on MCV and in 100 ppm group significant increase on MCHC were observed. Also in 50 ppm group an increase on SGOT enzyme level was observed. However, it was nonsignificant.
By observing the abnormality on the RBC count and SGOT enzyme level in the 50 ppm group, we concluded a slight toxicity effect for AuNPs and the threat potential of their use in human.


1. The Royal Society and the Royal Academy of Engineering. Nanoscience and nanotechnologies: opportunities and uncertainties. London, UK; 2004.
2. Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. Noninvasive imaging of quantum dots in mice. Bioconjug Chem. 2004; 15(1): 79-86.
3. Roszek B, De Jong WH, Geertsma RE. Nanotechnology in medical applications: state-of-the-art in materials and devices. RIVM report 265001001/2005. Bilthoven, the Netherlands; 2005.
4. Singh R, Pantarotto D, Lacerda L, Pastorin G, Klumpp C, Prato M, et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci U S A. 2006; 103(9): 3357-3362.
5. Donaldson K, Stone V, Clouter A, Renwick L, MacNee W. Ultrafine particles. Occup Environ Med. 2001; 58(3): 211-216.
6. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect. 2005; 113: 823-839.
7. Pissuwan D, Valenzuela SM, Cortie MB. Therapeutic possibilities of plasmonically heated gold nanoparticles. Trends Biotechnol. 2006; 24(2): 62-67.
8. Loghman A, Sohrabi Haghdoost I, Djeddi AN, Mortazavi P. Histopathologic and apoptotic effect of nanosilver in liver of broiler chickens. Afr J Biotechnol. 2012; 11(22): 6207-6211.
9. Stryer L. Biochemistry 5th. W.H., Freeman and company: New York; 2005. p. 596.
10. Joan F., Zilva, Peter R. Pannall and Philip D. Mayne, Clinical chemistry in Diagnosis and Treatment, 5th ed, 1988.p. 523.
11. Schumann G, Bonora R, Ceriotti F, Férard G, Ferrero CA, Franck PF, et al; IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 5. Reference procedure for the measurement of catalytic concentration of aspartate aminotransferase. Clin Chem Lab Med. 2002; 40(7): 725-33.
12. Zhang XD, Wu HY, Wu D, Wang YY, Chang JH, Zhai ZB, et al. Toxicologic effects of gold nanoparticles in vivo by different administration routes. Int J Nanomedicine. 2010; 5: 771-781.
13. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol. 2000; 32(1): 56-67.
14. Grance SR, Teixeira MA, Leite RS, Guimarمes EB, de Siqueira JM, de Oliveira Filiu WF, et al. Baccharis trimera: effect on hematological and biochemical parameters and hepatorenal evaluation in pregnant rats. J Ethnopharmacol. 2008; 117(1): 28-33.
15. Rhiouani H, El-Hilaly J, Israili ZH, Lyoussi B. Acute and sub-chronic toxicity of an aqueous extract of the leaves of Herniaria glabra in rodents. J Ethnopharmacol. 2008; 118(3): 378-386.
16. Cullen JM. Mechanistic classification of liver injury. Toxicol Pathol. 2005; 33(1): 6-8.
17. Thommas M, Derlin J. Text of Biochemistry with Clinical Correlations, A Wiley Medical Publication: New york; 1982.p. 185.
18. Harry R. Mathews, Richard A. Preed,Roger L.Miesfeld, Biochemistry a short course, Wiley Liss: U.S.A; 1997.p. 255.
19. Feldman M, Friedman LS, Brandt LJ. Sleisenger and fordtranʼs Gastrointestinal and Liver disease, Philadelphia: Saunders; 2002.
20. Ottaway G.H., Apps D.K., Bailliere T. Biochemistry. 4th ed. London; 1984.p. 322.
21. Okechukwu O, Segun O. A comparative analysis of six current histological classification schemes and scoring systems used in chronic hepatitis reporting. Rev Espatol. 2004; 37(3): 269-277.
22. Mgbojikwe LO. Acaricidal Properties of the Aqueous Stem Bark Extract of Adenium obesum. Ph.D. thesis, University of Jos. 2000.p.148-149.
23. L.Stryer, Biochemistry 5th. ed W.H. Freeman and company, New York, 2005. p. 596.
24. Tennekoon KH, Jeevathayaparan S, Kurukulasooriya AP, Karunanayake EH. Possible hepatotoxicity of Nigella sativa seeds and Dregea volubilis leaves. J Ethnopharmacol. 1991; 31(3): 283-289.
25. Rezaei Zarchi, Effect of Titanium dioxide nanoparticles on the amount of blood cells and liver enzymes in the wistar rats. JSSU. 2011; 19(5): 618-26.
26. Yasmin S, Das J, Stuti M, Rani M, D᾽Souza D, Sub Chronic Toxicity of Arsenic Trioxide on Swiss Albino Mice, International Journal of Environmental Sciences, 2011; 1(7): 1640-1647.
27. Rousselot P, Larghero J, Labaume S,Ziaee Ghahnavieh M., et al.,  Poupon J, Chopin M, Dosquet C, et al. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Eur J Haematol. 2004; 72(3): 166-171.